BillionToOne, Inc. (BLLN) Form 8-K — Aug 5, 2026
BillionToOne (NASDAQ: BLLN) reported Q2 2026 revenue of $109.4 million, up 64% from $66.6 million a year ago, and swung to GAAP net income of $8.1 million ($0.15 diluted EPS) from a $0.2 million loss in Q2 2025. Growth was broad-based: prenatal revenue rose 55% to $94.2 million, oncology revenue surged 176% to $13.7 million, 196,000 tests were delivered (+35%), and gross margin expanded 5 points to 70% on higher ASPs of $551. The company generated $5.1 million of free cash flow and $16.1 million of Adjusted EBITDA in the quarter.
Key figures
- Eps
- 0.15
- Revenue
- 109448000
- Guidance
- FY2026 revenue of $450.0-$465.0 million (48-52% growth over 2025); expects to continue generating profitability similar to current levels
- Net Income
- 8054000
- Total Debt
- 91031000
- Revenue Yoy
- 64%
- Total Assets
- 729696000
- Cash Position
- 548628000
- Ebitda q2
- $4.7 million
- Overall asp
- $551 (+21% YoY)
- Gross margin
- 70% vs 65% in Q2 2025
- H1 2026 revenue
- $217.8 million (+74% YoY)
- H1 debt issuance
- $30.0 million
- Operating margin
- 5%
- Free cash flow q2
- $5.1 million
- Adjusted ebitda q2
- $16.1 million
- H1 2026 net income
- $26.0 million
- Tests delivered q2
- 196000
- Oncology revenue q2
- $13.7 million (+176% YoY vs $4.9 million)
- Prenatal revenue q2
- $94.2 million (+55% YoY)
- Diluted eps basic q2
- 0.17
- H1 2026 free cash flow
- $16.0 million
- Income from operations q2
- $5.5 million vs $(1.6) million loss in Q2 2025
- Class a shares outstanding
- 42283900
- Class b shares outstanding
- 4542650
- Weighted diluted shares q2
- 54455523
Price after filing
Close on the filing date to close N calendar days later (from $142.25). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.